Laing R W, Warrington A P, Graham J, Britton J, Hines F, Brada M
Neuro-oncology Unit, Institute of Cancer Research, Sutton, Surrey, UK.
Radiother Oncol. 1993 Apr;27(1):22-9. doi: 10.1016/0167-8140(93)90040-f.
Twenty-two patients with recurrent glioma have been treated on a dose escalation protocol with fractionated stereotactic external beam radiotherapy (SRT). All had previously received radical radiotherapy (median dose 55 Gy) as part of the initial treatment. The dose of SRT was increased from 30 Gy in six fractions to 50 Gy in ten fractions. Median survival from the date of SRT was 9.8 months. There was no significant acute morbidity but five patients who received > or = 40 Gy developed steroid responsive neurological deterioration assumed to represent late radiation damage. The survival and toxicity in patients with recurrent glioma are comparable with interstitial therapy. Fractionated SRT is a noninvasive form of localised radiation which may be a suitable alternative to interstitial therapy in this group of patients.
22例复发性胶质瘤患者接受了立体定向分次外照射放疗（SRT）剂量递增方案治疗。所有患者在初始治疗时均接受过根治性放疗（中位剂量55 Gy）。SRT剂量从6次分割的30 Gy增加到10次分割的50 Gy。自SRT开始之日起的中位生存期为9.8个月。无明显急性并发症，但5例接受≥40 Gy照射的患者出现了类固醇反应性神经功能恶化，推测为迟发性放射损伤。复发性胶质瘤患者的生存期和毒性与间质治疗相当。分次SRT是一种局部放疗的非侵入性形式，在这类患者中可能是间质治疗的合适替代方法。
